Fig. 2: Prognostic impact of dynamic NK cell activity and methylated HOXA9 status. | British Journal of Cancer

Fig. 2: Prognostic impact of dynamic NK cell activity and methylated HOXA9 status.

From: NK cell activity and methylated HOXA9 ctDNA as prognostic biomarkers in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors

Fig. 2: Prognostic impact of dynamic NK cell activity and methylated HOXA9 status.The alternative text for this image may have been generated using AI.

Impact of NK cell activity (NKA) on progression-free survival (a, P = 0.003) and overall survival (b, P < 0.001). The red line represents the group of patients (NKA-low, n = 29) with an abnormally low level of IFNγ or who dropped to and remained at a low level (<250 pg/ml) at all available time points. The blue line represents the group of patients (NKA-mixed, n = 34) who experienced either an increase from abnormal to normal levels of IFNγ or vice versa. The green line represents the patients (NKA-high, n = 13) who maintained normal levels of IFNγ (≥250 pg/ml) at all available time points. Impact of methylated HOXA9 status after one cycle of treatment on progression-free survival (c, P = 0.018) and overall survival (d, P = 0.007). The red line represents the group of patients (HOXA9 + , n = 41) with detectable methylated HOXA9, while blue line represents the group of patients (HOXA9–, n = 32) with no detectable methylated HOXA9. Shaded areas represent the 95% confidence intervals.

Back to article page